drugset / Trial / NCT04594798
A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the effectiveness and safety of polatuzumab vedotin in combination with R-miniCHP in patients 75 years and older with DLBCL.
Timeline
- Start
- 2021-09-20
- Primary completion
- 2026-07-31
- Completion
- 2026-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Polatuzumab Vedotin | Other / unclassified | 1.8 mg/kg | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 400 mg/m2 | Intravenous |
| Background | Doxorubicin | Other / unclassified | 25 mg/m2 | Intravenous |
| Background | Prednisone | Other / unclassified | 40 mg/m2 | Oral |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |